Blood clot prevention drug shows promise in moderate COVID-19
NCT ID NCT07134738
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 34 times
Summary
This study looked at the safety of a drug called Dimolegin in preventing dangerous blood clots in adults hospitalized with moderate COVID-19. A total of 184 patients took the medicine once daily as part of their regular care. Researchers tracked bleeding events and other side effects to see if the drug was safe to use in this setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Infectious Diseases Clinical Hospital No. 1
Moscow, Russia
-
Infectious Diseases Hospital No. 2
Sochi, Russia
-
Regional Clinical Hospital No. 3
Chelyabinsk, Russia
-
Regional Infectious Diseases Clinical Hospital
Yaroslavl, Russia
-
Republican Clinical Hospital named after Professor A.F. Agafonov
Kazan', Russia
-
Tomsk Regional Hospital
Tomsk, Russia
Conditions
Explore the condition pages connected to this study.